3 terminated, 2 active not recruiting, 2 completed, 2 recruiting. 12 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Terminated 3, Active not recruiting 2, Completed 2, Recruiting 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 7 | Active not recruiting 2, Unknown 2, Completed 1, Recruiting 1, Terminated 1 |
Follow Ovarian Cancer Recurrent: new trials by email Literature Review of Ovarian Cancer Recurrent trials Research Report on Ovarian Cancer Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. OPB-201 - Endometrial Cancer Recurrent, Endometrial Cancer | Phase 1 | Recruiting | Outpace Bio, Inc. | 30 | 2026-06-30 | 2026-10-26 |
| A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer COM701, Normal Saline - Ovarian Cancer, Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Active not recruiting | Compugen Ltd | 60 | 2025-07-21 | 2026-10-06 |
| A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer OPB-101 - Ovarian Cancer Recurrent, Ovarian Cancer | Phase 1 | Terminated | Outpace Bio, Inc. | 3 | 2025-06-16 | 2026-10-26 |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). Raludotatug Deruxtecan, Carboplatin, Paclitaxel - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 605 | 2025-04-15 | 2026-10-30 |
| Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer M4344+Niraparib - Ovarian Cancer Recurrent | Phase 1 | Withdrawn | University of Alabama at Birmingham | 2023-05-01 | 2026-06-05 | |
| Microtransplantation for Ovarian Cancer microtransplantation, HLA-mismatched donor peripheral stem cell infusion - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Unknown | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 60 | 2021-10-01 | 2021-10-27 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
| Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer Rintatolimod, Pembrolizumab, Cisplatin - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Active not recruiting | Robert Edwards | 24 | 2019-01-28 | 2026-02-12 |
| A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer. Doxorubicin Hydrochloride Liposome Injection - Ovarian Cancer Recurrent | Phase 1 | Completed | Ayana Pharma Ltd., | 52 | 2018-08-29 | 2019-11-20 |
| Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer Tumor Infiltrating Lymphocytes (TIL), Interferon Alfa 2A, Carboplatin - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Unknown | Leiden University Medical Center | 12 | 2018-08-01 | 2021-04-01 |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer Oregovomab, Poly ICLC - Cancer of Ovary, Neoplasms, Ovarian | Phase 1 | Terminated | CanariaBio Inc. | 10 | 2017-05-30 | 2020-12-22 |
| A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse Lenalidomide - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Completed | ARCAGY/ GINECO GROUP | 67 | 2009-05-01 | 2016-03-17 |
Ovarian Neoplasms (7) · Endometrial Neoplasms (2) · Carcinoma (1) · Carcinoma, Endometrioid (1) · Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Krukenberg Tumor (1) · Ovarian Diseases (1) · Recurrence (1) · Uterine Diseases (1)
Adnexal Diseases (7) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genital Diseases (7) · Genital Diseases, Female (7) · Genital Neoplasms, Female (7) · Gonadal Disorders (7) · Neoplasms (7) · Neoplasms by Site (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7) · Ovarian Diseases (6) · Uterine Neoplasms (2)
Carboplatin (2) · Paclitaxel (2) · pembrolizumab (2) · 1-dodecylpyridoxal (1) · Bevacizumab (1) · Cisplatin (1) · Gemcitabine (1) · Interferon alpha-2 (1) · Lenalidomide (1) · Saline Solution (1) · liposomal doxorubicin (1) · oregovomab (1) · poly ICLC (1) · poly(I).poly(c12,U) (1)
Outpace Bio, Inc. (2) · ARCAGY/ GINECO GROUP (1) · Ayana Pharma Ltd., (1) · CanariaBio Inc. (1) · Compugen Ltd (1) · Elucida Oncology (1) · Leiden University Medical Center (1) · Merck Sharp & Dohme LLC (1) · Robert Edwards (1) · The Affiliated Hospital of the Chinese Academy of Military Medical Sciences (1) · University of Alabama at Birmingham (1)
United States (7) · France (2) · Israel (2) · Australia (1) · Canada (1) · China (1) · India (1) · Netherlands (1) · South Korea (1) · Spain (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Christopher Nicodemus, MD FACP (1) · Judith Kroep, MD, PhD (1) · Rakesh J Patel, MD Pharm (1) · Rebecca C Arend, MD, MSPH (1) · Robert Edwards, MD (1)